Navigation Links
The Majority Of Oncologists Will Begin Using Biosimilar Monoclonal Antibodies Within 12 Months Of Launch
Date:10/31/2013

EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. and European oncologists will cautiously adopt biosimilar monoclonal antibodies initially; only a minority of oncologists say they will initially adopt biosimilar monoclonal antibodies in many or all of their patients. However, the majority of surveyed oncologists say that they expect to prescribe biosimilar trastuzumab, cetuximab, bevacizumab or rituximab within the first 12 months of launch, and only a minority does not expect to prescribe biosimilar monoclonal antibodies.

The Biosimilars Advisory Service report entitled Physician Perspectives on G-CSFs and Monoclonal Antibodies in Oncology provides analysis of survey results from over 180 U.S. and European oncologists across a wide range of solid tumor indications and hematological malignancies. The report also finds that development of new and improved originator biologic therapies intended to shift treatment practices can limit the extent of biosimilar penetration.

"In an era of severe cost constraints, setting appropriate biobetter prices is critical, especially when lower-cost biosimilar versions of the originator molecule are available," said BioTrends Research Group's Senior Director of Biosimilars Research Andrew Merron, Ph.D. "A successful biobetter should address clinically relevant unmet needs; for example, the majority of surveyed oncologists would prescribe a biobetter priced 5 percent more than the originator if it offered a modest improvement in efficacy and the same safety and dosing as the originator. While developing more efficacious agents is especially important in oncology indications, improving delivery is another opportunity. Roche recently gained European approval of subcutaneous Herceptin; if biosimilar trastuzumab costs 20 percent less than subcutaneous and intravenous Herceptin, the majority of surveyed French oncologists would prefer subcutaneous Herceptin in the maintenance setting. However, a greater proportion of them would choose the biosimilar than the intravenous brand."

Surveyed oncologists also revealed pivotal insights to understanding the current and future uptake of biosimilars, including their level of familiarity, concerns, drivers and constrainers of adoption, views on indication extrapolation, attitudes towards reimbursement and the clinical trial requirements for biosimilars.

The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst insight addressing key market changes and opportunities, therapeutic area-specific primary research and forecasting modules.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NEW POLL: Majority of Allegan County Voters Oppose Prescription Only PSE Requirements
2. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
3. Majority of Springfield Voters Oppose Prescription Only PSE Requirements
4. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
5. New National Survey Shows Majority of Americans Confident About Choosing Health Coverage
6. Allscripts adopts majority voting policy for directors
7. BD Completes Sale of Majority of Discovery Labware Unit
8. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
9. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
10. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
11. Differences Over Pathways Developed by Oncologists and MCOs May Create Conflict Over Prescribing Decisions in Early-Line Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... de 2016  A Proliant Biologicals anuncia, com ... bovina (BSA -- Bovine Serum Albumin ) ... Norte da Nova Zelândia, em Feilding. ... da Proliant nos EUA, localizada em ... dos equipamentos foram feitos de forma a reproduzir ...
(Date:2/11/2016)... , Ill. and INDIANAPOLIS , Feb. ... for many young people, but for those with type ... only do these students juggle class schedules, assignments and ... living with type 1 diabetes. On top of that, ... time. Diabetes Scholars Foundation (Foundation) Lilly ...
(Date:2/11/2016)... , February 11, 2016 ... release of a new research report, titled "Sports Medicine Devices ... Forecast, 2013 - 2019". According to the report, the global ... 4.40% CAGR from 2013 to 2019, growing from a value ... --> --> The global ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... , ... PharmMD CEO Robert Yeager announced today ... contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will include healthcare ... breaches for the Part D Star Rating improvement and Medication Therapy Management firm. ...
(Date:2/11/2016)... NY (PRWEB) , ... February 11, 2016 , ... ... enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to include ... in vein illumination with an estimated 85% share of the market, facilitates adherence ...
(Date:2/11/2016)... ... 11, 2016 , ... The annual list showcases the 20 Most Promising SharePoint ... dedication and commitment to the SharePoint ecosystem. A panel of experts and members ... is to recognize and promote technology entrepreneurship. , The survey was made at ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... ergoFET force gauges used in physical therapy, occupational therapy and sports medicine clinics, ... resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... in significantly higher rates of several common cancer screenings, especially among women. Cancer ... outcomes and survival rates. , The study,“What Does Medicaid Expansion Mean for ...
Breaking Medicine News(10 mins):